veldoreotide
PeptideexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2019 (NCT04138342)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Somatostatin receptor 4AGONIST
Somatostatin receptor 4 agonist
- Somatostatin receptor 5AGONIST
Somatostatin receptor 5 agonist
- Somatostatin receptor 2AGONIST
Somatostatin receptor 2 agonist
- SomatostatinSupplementation
SST supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC(O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](Cc2ccccc2)NC1=O- Mol. weight
- 1123.33 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989911 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04138342 | Phase 1 | Sep 15, 2019 | Al Azhar University, Qassim University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Qassim University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1